Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. HER2 signaling inhibitors reduce TUBB3 RNA expression.
  • Fig. S2. Capecitabine treatment does not alter βIII-tubulin expression.
  • Fig. S3. Increase in proliferation of trastuzumab-resistant BT-474Br cells.
  • Fig. S4. Small-molecule HER2 signaling inhibitors reduce TUBB3 expression in trastuzumab-resistant cells.
  • Fig. S5. JQ-1 does not inhibit the efficacy of HER2 signaling inhibitors.
  • Fig. S6. BET inhibitors increase βIII-tubulin expression in breast cancer cell lines.
  • Fig. S7. JQ-1 treatment sensitizes HCC1954 cells to VRB.
  • Fig. S8. Knockdown of TUBB3 reduces the efficacy of combination therapy.
  • Fig. S9. Toxicity analysis of mice treated with combination therapy.
  • Fig. S10. Radiation increases the expression of βIII-tubulin.
  • Fig. S11. MZF-1 expression correlates inversely with HER2 expression in BMs.
  • Fig. S12. Effect of MZF-1 knockdown on proliferation of cells in vitro and in vivo.
  • Fig. S13. Effect of MZF-1 overexpression on proliferation of cells in vitro and in vivo.
  • Fig. S14. MZF-1 knockdown results in loss of effectiveness of combination therapy.
  • Fig. S15. Knockdown of c-Myc and/or MZF-1 increases TUBB3 expression.
  • Fig. S16. Illustration describing the mechanism of MZF-1–mediated repression of TUBB3.
  • Fig. S17. Unprocessed and uncropped Western blots of Figs. 1 to 3.
  • Fig. S18. Unprocessed and uncropped Western blots of Figs. 6 and 7.
  • Fig. S19. Unprocessed and uncropped Western blots of figs. S2, S4, and S6.
  • Fig. S20. Unprocessed and uncropped Western blots of figs. S8, S10, S13, and S15.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Word format). Promoter and cDNA sequences.
  • Data file S2 (Microsoft Excel format). shRNA and primer sequences.
  • Data file S3 (Microsoft Excel format). Raw data.